Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Molecular Insight Pharmaceuticals, Inc. (MIPI)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | S-1/A | S-1/A |
| Revenues | 5.5 | 0.5 | 0.7 | 16.6 | 8.7 | 5.3 | 2.7 | 2,217.0 |
| Revenue growth | 1057.9% | -35.1% | -95.6% | 92.3% | 63.3% | 96.2% | -99.9% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 26.8 | 19.9 | 8.9 | 4.0 | 7,676.9 |
| Gross profit | 5.5 | 0.5 | 0.7 | -10.2 | -11.2 | -3.6 | -1.3 | -5,459.9 |
| Gross margin | 99.4% | 100.0% | 100.0% | -61.4% | -129.8% | -68.0% | -49.6% | -246.3% |
| Selling, general and administrative [+] | 19.8 | 20.9 | 14.8 | 8.6 | 10.0 | 3.1 | 1.2 | 1,333.7 |
| General and administrative | 19.8 | 20.9 | 14.8 | 8.6 | 10.0 | 3.1 | 1.2 | 1,333.7 |
| Other operating expenses | 31.9 | 41.5 | 43.6 | 7.7 | -2.6 | 1.6 | 0.8 | 259.1 |
| EBITDA [+] | -45.3 | -61.0 | -57.0 | -26.2 | -18.5 | -8.2 | -3.2 | -7,048.8 |
| EBITDA growth | -25.7% | 7.1% | 117.3% | 41.6% | 125.0% | 155.1% | -100.0% | |
| EBITDA margin | -825.0% | -12857.1% | -7794.6% | -157.6% | -213.9% | -155.3% | -119.4% | -317.9% |
| Depreciation and amortization | 0.9 | 0.9 | 0.7 | 0.3 | 0.1 | 0.1 | 0.1 | 3.9 |
| EBIT [+] | -46.3 | -61.9 | -57.7 | -26.5 | -18.6 | -8.3 | -3.3 | -7,052.7 |
| EBIT growth | -25.3% | 7.4% | 117.5% | 42.2% | 123.8% | 151.2% | -100.0% | |
| EBIT margin | -842.1% | -13047.3% | -7893.4% | -159.4% | -215.5% | -157.3% | -122.8% | -318.1% |
| Interest expense, net [+] | 20.2 | 19.5 | 2.2 | 0.7 | -0.3 | 0.0 | 0.0 | 2.2 |
| Interest expense | 21.3 | 23.1 | 4.7 | 1.2 | 0.1 | 0.0 | 0.0 | 5.5 |
| Interest income | 1.1 | 3.6 | 2.6 | 0.5 | 0.5 | 0.0 | 0.0 | 3.4 |
| Other income (expense), net | | 0.1 | | | | | 0.0 | -28.6 |
| Pre-tax income | -66.5 | -81.3 | -59.8 | -27.3 | -18.3 | -8.3 | -3.3 | -7,083.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -0.1 | -0.1 | -0.1 | -32.2 | 0.0 | 0.0 | 0.0 | -7.1 |
| Net margin | -1.2% | -17.1% | -8.4% | -193.7% | -0.3% | -0.2% | -0.1% | -0.3% |
| |
| Basic EPS [+] | ($2.64) | ($3.25) | ($2.65) | ($7.18) | ($5.30) | ($2.55) | ($1.13) | ($0.63) |
| Growth | -18.8% | 22.6% | -63.1% | 35.5% | 107.8% | 125.7% | 79.9% | |
| Diluted EPS [+] | ($2.64) | ($3.25) | ($2.65) | ($7.18) | ($5.30) | ($2.55) | ($1.13) | ($0.63) |
| Growth | -18.8% | 22.6% | -63.1% | 35.5% | 107.8% | 125.7% | 79.9% | |
| |
| Shares outstanding (basic) [+] | 0.0 | 0.0 | 0.0 | 4.5 | 0.0 | 0.0 | 0.0 | 11.3 |
| Growth | 0.7% | 8.3% | -99.5% | 106339.9% | 11.7% | 7.7% | -100.0% | |
| Shares outstanding (diluted) [+] | 0.0 | 0.0 | 0.0 | 4.5 | 0.0 | 0.0 | 0.0 | 11.3 |
| Growth | 0.7% | 8.3% | -99.5% | 106339.9% | 11.7% | 7.7% | -100.0% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|